Type 2 immunity‐driven diseases: Towards a multidisciplinary approach

Hassoun, Dorian; Malard, O.; Barbarot, S.; Magnan, A.; Colas, Luc

doi:10.1111/cea.14029

Cited by 17 publications

(27 citation statements)

References 165 publications

(205 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patient participation, prediction of treatment success, prevention of disease and personalized care will help to choose the best specific treatment for the global airway and skin of the patient and will help increase patient satisfaction, therapy compliance and disease control ( 28 ). Furthermore, a multidisciplinary approach by the implementation of integrated care pathways (ICPs) could help to focus on the prevention, detection, non-pharmacological management and treatment of Type 2 comorbidities ( 2 , 12 , 29 – 32 ). According to our findings, this holistic approach requires assessment of patients across the following key domains: GPs, psychological services, pulmonologists, dermatologists and ENT specialists.…”

Section: Discussionmentioning

confidence: 99%

“…Optimizing communication exchange between first-, second- and third-line health care providers will contribute to the continuity of care, multidisciplinary evaluation and regular follow-up of patients. However, further clinical trials to assess multidisciplinary approaches in comparison to standard care are still needed to better document the improvement of overall care and outcome of patients with Type 2 inflammation ( 2 , 30 ). Additional themes cited by patients for future research projects are mainly the following: connection between lungs-nose-skin, causes of Type 2 inflammation, effect of COVID-19 on chronic respiratory diseases, link between food and Type 2 inflammation and new treatment options.…”

Section: Discussionmentioning

confidence: 99%

“…Biologics are monoclonal antibodies that, in this case, target Type 2 mediators. Asthma, AD and CRSwNP are inflammatory diseases among subgroups that share common pathophysiological mechanisms which explain their frequent co-existence ( 1 , 2 ). Targeting the key drivers of Type 2 inflammation has a therapeutic effect on both AD, asthma and CRSwNP ( 12 , 33 , 34 ).…”

Section: Discussionmentioning

confidence: 99%

“…Chronic rhinosinusitis with nasal polyps (CRSwNP), asthma and atopic dermatitis (AD) are chronic inflammatory diseases of the upper airways, lower airways and the skin, respectively. The majority of these patients share a common pathogenesis, called Type 2 inflammation, with different T-helper 2 and ILC2 (type 2 innate lymphoid cells) cytokines driving the chronicity of inflammation in the different organs ( 1 , 2 ). Globally, the prevalence of Type 2 inflammatory diseases is increasing with CRSwNP, asthma and AD currently affecting up to 3%, 1–18% and 10% of the population respectively ( 3 – 5 ).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

White Paper on European Patient Needs and Suggestions on Chronic Type 2 Inflammation of Airways and Skin by EUFOREA

Prins

Raap²,

Mueller³

et al. 2022

Front. Allergy

View full text Add to dashboard Cite

BackgroundType 2 inflammation underlies the chronicity of disease in subgroups of patients with asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and atopic dermatitis (AD), that often co-exist. Although several studies have investigated the unmet needs of asthma, AD and CRSwNP as such, little is known about the similarities and differences in experiences and perspectives of the current management of patients with comorbid Type 2 inflammatory diseases.AimsTo improve insight into the common and organ-specific needs of patients with Type 2 inflammation and comorbidities, allowing the formulation of recommendations to better address these needs in the future.MethodologyThis qualitative study was conducted between July 2021 and December 2021 using semi-structured face-to-face or telephone interviews with patients suffering from year-long severe chronic Type 2 inflammation and at least one co-morbid inflammatory condition. Seven participating academic centers in Europe interviewed asthma (Copenhagen and Leuven), CRSwNP (London, Amsterdam and Crete) and/or AD (Oldenburg and Zurich) patients on patient characteristics, disease severity, shortcomings of current care pathways and suggestions for improvement of care. Transcripts were analyzed using an inductive thematic analysis approach.ResultsEighty-one patients with severe Type 2 inflammation and comorbidities were interviewed. Similar needs were recognized by patients with Type 2 inflammation, with both a lack of coordination in care and a lack of a real cure reported as being most frustrating. However, several needs are specific to asthma, CRSwNP and AD. Suggestions for improvement of care were generic across diseases, such as the implementation of a multidisciplinary approach, the improved facilitation of access to better treatments, the increase of general awareness on disease burden, and better educational programs for healthcare providers and patients. Of note, patients with CRSwNP also stated the need for alternatives to sinus surgery, whereas patients with asthma requested better medical care to prevent exacerbations and patients with AD would warmly welcome the reimbursement of emollients.ConclusionPatients with asthma, CRSwNP and AD have shared unmet needs that need to be addressed by physicians, the academic community and health policy makers. This survey provides unique recommendations made by patients for the implementation of better care.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

White Paper on European Patient Needs and Suggestions on Chronic Type 2 Inflammation of Airways and Skin by EUFOREA

Prins

Raap²,

Mueller³

et al. 2022

Front. Allergy

View full text Add to dashboard Cite

show abstract

“…By contrast, in macaques, scRNA-seq found that IL-4 and IL-13 were particularly highly produced by recruited mast cells, indicating that there may be some species specific variation in the cell types that are producing type 2 cytokines ( 15 ). Beyond IL-4 and IL-13, it seems likely that other cytokines and signals are also required to drive necrotic granuloma formation, as elevated levels of IL-4 and IL-13 are observed in many inflammatory responses that do not lead to granuloma formation ( 80 ). The identity of these potential accessory factors is unknown, but experiments characterizing the induction of the epithelial cell-cell adhesion molecule E-cadherin in macrophages in culture found that E-cadherin induction by IL-4 and IL-13 could be enhanced by costimulation with IL-10 and TGFβ ( 52 ), suggesting that these two cytokines may act as accessory factors, facilitating granuloma formation through potentiation of the macrophage-epithelial transitions that underlie granuloma formation ( 46 ).…”

Section: Molecular Reprogramming Of Macrophages and Host Determinants...mentioning

confidence: 99%

In the Thick of It: Formation of the Tuberculous Granuloma and Its Effects on Host and Therapeutic Responses

Cronan

2022

Front. Immunol.

View full text Add to dashboard Cite

The defining pathology of tuberculosis is the granuloma, an organized structure derived from host immune cells that surrounds infecting Mycobacterium tuberculosis. As the location of much of the bacteria in the infected host, the granuloma is a central point of interaction between the host and the infecting bacterium. This review describes the signals and cellular reprogramming that drive granuloma formation. Further, as a central point of host-bacterial interactions, the granuloma shapes disease outcome by altering host immune responses and bacterial susceptibility to antibiotic treatment, as discussed herein. This new understanding of granuloma biology and the signaling behind it highlights the potential for host-directed therapies targeting the granuloma to enhance antibiotic access and tuberculosis-specific immune responses.

show abstract